Moreover, the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus–Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) trial [1,2] showed that DPPIV inhibition reduces albuminuria in T2DM subjects with CKD, suggesting that the DPPIV inhibitors may confer renoprotective effects that extend beyond glycemic control. The gene discussed is DPP4; the disease is chronic kidney disease.